Purple Biotech's IM1240 Tri-specific Antibody Shows Expanded Therapeutic Window in Toxicology Study
PPBT sits 30% above its 52-week low of $0.533.
Summary
Purple Biotech announced positive preclinical toxicology results for its lead CAPTN-3 platform candidate, IM1240, demonstrating an expanded therapeutic window and improved safety profile.
Key Events · Product Development and Regulatory · PPBT
-
Positive Toxicology Results
IM1240, a CAPTN-3 tri-specific antibody, successfully completed a non-human primate toxicology study.
-
Expanded Therapeutic Window Demonstrated
The study showed IM1240 could be dosed up to 300-fold higher than a non-capped comparator with significantly reduced immune-related toxicity and minimal cytokine release.
-
Favorable Pharmacokinetic Profile
IM1240 exhibited increased systemic exposure and a prolonged circulating half-life.
-
Advancing Towards Clinical Trials
The company plans regulatory submission for first-in-human clinical trials for IM1240 in the second half of 2026.
Analysis · PPBT · Life Sciences
The successful completion of a non-human primate toxicology study for IM1240 is a significant de-risking event for Purple Biotech's lead tri-specific antibody program. The data showing IM1240 can be dosed 300-fold higher than a comparator with minimal immune-related toxicity, including reduced cytokine release, addresses a key challenge in T-cell engager therapies. This expanded therapeutic window and favorable pharmacokinetic profile provide a strong foundation for advancing IM1240 towards first-in-human clinical trials, with regulatory submission anticipated in the second half of 2026. This milestone enhances the program's potential and provides a clear path forward for the company's CAPTN-3 platform.
At the time of this filing, PPBT was trading at $0.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7M. The 52-week trading range was $0.53 to $4.55. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.